Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM
Randomized Phase II/III Trial of Radiotherapy Plus Concomitant and Adjuvant Temozolomide With or Without Hydroxychloroquine, Rapamycin for Newly Diagnosed Glioblastoma
Sponsor: Johnpro Biotech, Inc.
This PHASE2/PHASE3 trial investigates Glioblastoma and is currently ongoing. Johnpro Biotech, Inc. leads this study, which shows 11 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2/PHASE3
-
May 2025 — Sep 2025 [monthly]
Unknown PHASE2/PHASE3
Status: Recruiting → Unknown
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2021 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 6 earlier versions
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2020 — Aug 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2020 — Jun 2020 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Feb 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Johnpro Biotech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .